Kathleen E. Walsh - 03 Jun 2026 Form 4 Insider Report for Beam Therapeutics Inc. (BEAM)

Reporting relationship: Director
Issuer ticker: BEAM
Reported as of: 03 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Jun 2026, 16:05:10 UTC
Prior SEC filing: 06 Jun 2025
Source filing: View source filing
Reporting owner signature: By: /s/ Christine Bellon, Attorney-in-fact

Key filing fact

Kathleen E. Walsh filed Form 4 for Beam Therapeutics Inc. (BEAM) on 05 Jun 2026.

Key facts

This page summarizes Kathleen E. Walsh's Form 4 filing for Beam Therapeutics Inc. (BEAM).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 05 Jun 2026, 16:05.

Change

Previous filing in this sequence was filed on 06 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001667866 Primary reporting owner

Walsh Kathleen E

Relationship: Director
Address: C/O BEAM THERAPEUTICS INC.,, 238 MAIN STREET, CAMBRIDGE
Signature: By: /s/ Christine Bellon, Attorney-in-fact
Signature date: 05 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BEAM transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +19,676
Change %
Price: $0.000000^*
Shares after: 19,676
Date: 03 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 19,676
Exercise price: $29.55
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.